Somatic mutations of the HER2 in metastatic breast cancer

Tumor Biology

Volumn 35, Issue 12, 2014, Pages 11851-11854

  Fang, Yi ^a   Jiang, Yanxia ^b   Wang, Xin ^a   Yang, Xue ^a   Gao, Yinqi ^a   Wang, Jing ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b Jingdezhen First People's Hospital   (China)

Author keywords

Dimerization; ErbB2; HER2; Phosphorylation; Somatic mutations; Therapeutic antibody

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; BLADDER CANCER; BREAST METASTASIS; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; EGFR GENE; EXON; FEMALE; GENE INSERTION; GENE SEQUENCE; HER2 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; ONCOGENE K RAS; PRIORITY JOURNAL; PROSTATE CANCER; SOMATIC MUTATION; WILD TYPE; BREAST NEOPLASMS; GENETICS; METASTASIS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84925285811     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2414-y     Document Type: Article

References (17)

1. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463–75.
2. Hudis CA. Current status and future directions in breast cancer therapy. Clin Breast Cancer. 2003;4 Suppl 2:S70–5.
3. Zhang Q et al. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proc Natl Acad Sci U S A. 2012;109(33):13237–42.
4. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;284(1):54–65.
5. Normanno N et al. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer. 2003;10(1):1–21.
6. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.
7. Bunn PA et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res. 2001;7(10):3239–50.
8. Warren CM, Landgraf R. Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal. 2006;18(7):923–33.
9. Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–26.
10. Nahta R, Esteva FJ. Molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8(6):667–74.
11. Nahta R et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269–80.
12. Shigematsu H et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–46.
13. Stephens P et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431(7008):525–6.
14. Gatzemeier U et al. Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol. 2004;15(1):19–27.
15. Gazdar AF et al. Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers? Trends Mol Med. 2004;10(10):481–6.
16. Dibb NJ, Dilworth SM, Mol CD. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer. 2004;4(9):718–27.
17. Britten CD. Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther. 2004;3(10):1335–42.